Health ❯ Healthcare ❯ Clinical Trials

Cancer Treatment

Survival Rates Immunotherapy Breast Cancer CAR T-cell Therapy Prostate Cancer Ovarian Cancer Combination Therapy AML Treatment Strategies Personalized Therapy Immunotherapeutics Tandem CAR T-cells Therapeutics Immunotherapy Drugs Drug Efficacy Multiple Myeloma Immunotherapy Strategies Dormant Cells EGFR-mutant NSCLC Drug Development Pan-Cancer Therapies Advanced Colorectal Cancer HER2-positive Breast Cancer Patient Enrollment Therapeutic Vaccines Chronic Lymphocytic Leukemia Colorectal Cancer Radiation Therapy Tumor Microenvironment Proton Beam Therapy Intensity-Modulated Radiation Therapy Oropharyngeal Cancer Triple-Negative Breast Cancer CAR-T Cell Efficacy Immune Response CAR-NK Cells Neuroendocrine Tumors FGFR2b-targeted Therapy Targeted Therapies PARP Inhibitors Glioblastoma Trials CAR-T Cell Therapy Immunotherapy Research Personalized Medicine

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

Rapid one-hour peak with a clean safety profile positions the CXCR4 antagonist for Phase 3 planning.

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

Kisqali Cuts Recurrence in 5-Year NATALEE Results for High-Risk Early HR+/HER2- Breast Cancer

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

TORPEdO Phase III Finds No One-Year Advantage for Proton Therapy Over IMRT in Oropharyngeal Cancer

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

Engineered Salmonella Triggers Tumor Immune Hubs, Slows Colorectal Cancer in Mice

City of Hope Launches National Clinical Trial Network to Expand Access to Cancer Treatments

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort

Repurposed Drugs Clear Dormant Breast Cancer Cells in Phase II Trial

Remote Coaching Program Drives One-Year Weight Loss in Large Breast Cancer Trial

AI-Informed Pipeline Accelerates Bi-Specific CAR-T Design and Clears Tumors in Mice

CDK12/13 Degraders Activate STING-Mediated Immunity and Enhance Checkpoint Therapy

UF Researchers Develop Universal mRNA Vaccine That Primes Immune System Against Tumors

UCSF Researchers Target Variant Bladder Cancer With CAR-T Therapy

Baylor Researchers Identify Flavonoids That Target Bladder Cancer Cells